Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is a promising biopharmaceutical company with a strong focus on precision medicine for neurodegenerative diseases. The company's innovative approach using active immunotherapy has several advantages over traditional passive immunotherapy, including reduced cost and longer-lasting responses. Their pipeline looks promising, with multiple clinical programs targeting misfolded proteins associated with AD and PD, along with a versatile platform for developing both small molecule imaging agents and oral anti-aggregation agents. With upcoming data readouts for various programs, including the potential for significant plaque removal and improvements in motor and cognitive function in the PD program, AC Immune's potential for success is high.

Bears say

AC Immune is focusing on developing vaccines to potentially treat neurodegenerative diseases associated with protein misfolding. However, there are technical risks to these programs as the vaccines make assumptions about the structure of the toxic species and success may be dependent on biomarkers that are not fully established. Additionally, the company's AD program may be more biologically de-risked than their PD program due to the correlation between plaque clearance and cognitive benefit, while the readout for the AD trial is also better established compared to the PD trial.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.